Supply of OPV by

M/s RITES

Twenty Fourth Meeting Of

the India Expert Advisory Group (IEAG) for Polio Eradication

on15th March 2012

By S N Panda GM/Rites

Outline of Presentation

• Introduction• Procurement Objective• Supply overview• Our Experience• Recommendation

Introduction• M/s RITES Limited(A PSU under Ministry of Rlys)

assisting the Department of Health & Family Welfare as Procurement Agent for procurement of OPVs funded by External Agencies like World Bank since May’ 2010 previously handled by UNICEF

• In FY 2010-11 five indents were processed for four types of vaccines like bOPV, tOPV,mOPV1 and mOPV3

• In FY 2011-12 two indents were processed for two types of vaccines like bOPV and tOPV only

• In FY 2012-13 one indent is already processed for bOPV (Supply in April – June 2012)

Vaccine Supply Objectives

To ensure a sustained and uninterrupted supply of quality vaccines

Through

• WHO Prequalification• Appropriate contracting

Supply of OPV FY OPV Indent Qty

(Million Doses)Procured Qty (Million Doses)

Reasons for short procurement

2010-11 bOPV 162 100 No offer /No responsive offertOPV 471 247

2011-12 bOPV 275 275

tOPV 450 109* No offer /No responsive offer/conditional offer

2012-13 bOPV 340 238 No offer /No responsive offer for short notice supply

bOPV 300 Procurement Plan under approval

tOPV 450

*One of the bidder’s manufacturing process was taken on review by WHO during decision process

Response From Suppliers in 2011-12

OPV Number of prequalified Firms

Number of Participated Firms

Remarks

bOPV 6 3 Only Indian suppliers participated

tOPV 6 3 One foreign supplier participated

Installed Capacity of OPV Suppliers (Participated in RITES Tender)

Firm Name Installed Capacity Million Doses per annum

M/s Panacea Biotec 1600

M/s Haffkine 600

M/s Sanofi Pasture 4000

M/s Bharat Biotech 1382

Our OPV Procurement Experience

• 50% of qualified suppliers participated in Bid• Mostly suppliers from India participated

though it was a LIB except M/s Sanofi from France

• No offer for full Bid quantity• Appreciable gap in offered price of different

suppliers

Reasons for low response

• Demand- Supply gap• Shortage of bulk in International market• Non participation of foreign suppliers due to (i)

supply of OPV in short notice (ii) shelf life of minimum 18 months on the date

of arrival at port of entry in India (iii) Marking of “CGS Not for Sale” on primary

packaging

OPV Requirement for 2012-13 rounds

OPV Indent Qty (Million Doses)

Delivery Requirement

Remarks

bOPV 50 31/08/2012 Procurement Plan Under Approval100 28/02/2013

50 31/03/2013

100 31/05/2013

Total 300

tOPV 225 31/12/2012

225 31/01/2013

Total 450

Recommendation of RITES• Indent should be sent at least 12 months in

advance with respect to supply requirement so that tender can be finalised six months prior to requirements. This implies advanced planning and long term IEAG recommendations.

• Residual Shelf Life of vaccine at the time of supply as per Indian Drug & Cosmetic Act (i.e. 60% of total life of 24 months) instead of 18 months

• Waiver of “CGS Not for Sale” on primary packaging

Thank You